101 related articles for article (PubMed ID: 35039048)
1. Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer.
Yang Z; Liang SQ; Zhao L; Yang H; Marti TM; Hegedüs B; Gao Y; Zheng B; Chen C; Wang W; Dorn P; Kocher GJ; Schmid RA; Peng RW
J Exp Clin Cancer Res; 2022 Jan; 41(1):25. PubMed ID: 35039048
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.
Yang Z; Liang SQ; Saliakoura M; Yang H; Vassella E; Konstantinidou G; Tschan M; Hegedüs B; Zhao L; Gao Y; Xu D; Deng H; Marti TM; Kocher GJ; Wang W; Schmid RA; Peng RW
EMBO Mol Med; 2021 Sep; 13(9):e13193. PubMed ID: 34369083
[TBL] [Abstract][Full Text] [Related]
3. SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer.
Wang X; Zhang H; Sapio R; Yang J; Wong J; Zhang X; Guo JY; Pine S; Van Remmen H; Li H; White E; Liu C; Kiledjian M; Pestov DG; Steven Zheng XF
Nat Commun; 2021 Apr; 12(1):2259. PubMed ID: 33859191
[TBL] [Abstract][Full Text] [Related]
4. Targeting GRP78 suppresses oncogenic KRAS protein expression and reduces viability of cancer cells bearing various KRAS mutations.
Ha DP; Huang B; Wang H; Rangel DF; Van Krieken R; Liu Z; Samanta S; Neamati N; Lee AS
Neoplasia; 2022 Nov; 33():100837. PubMed ID: 36162331
[TBL] [Abstract][Full Text] [Related]
5. mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.
Malone CF; Emerson C; Ingraham R; Barbosa W; Guerra S; Yoon H; Liu LL; Michor F; Haigis M; Macleod KF; Maertens O; Cichowski K
Cancer Discov; 2017 Dec; 7(12):1450-1463. PubMed ID: 28963352
[TBL] [Abstract][Full Text] [Related]
6. CRISPR and KRAS: a match yet to be made.
Bender G; Fahrioglu Yamaci R; Taneri B
J Biomed Sci; 2021 Nov; 28(1):77. PubMed ID: 34781949
[TBL] [Abstract][Full Text] [Related]
7. Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.
Mukhopadhyay S; Huang HY; Lin Z; Ranieri M; Li S; Sahu S; Liu Y; Ban Y; Guidry K; Hu H; Lopez A; Sherman F; Tan YJ; Lee YT; Armstrong AP; Dolgalev I; Sahu P; Zhang T; Lu W; Gray NS; Christensen JG; Tang TT; Velcheti V; Khodadadi-Jamayran A; Wong KK; Neel BG
Cancer Res; 2023 Dec; 83(24):4095-4111. PubMed ID: 37729426
[TBL] [Abstract][Full Text] [Related]
8. Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality.
Liu F; Xin M; Feng H; Zhang W; Liao Z; Sheng T; Wen P; Wu Q; Liang T; Shi J; Zhou R; He K; Gu Z; Li H
Sci Adv; 2024 Mar; 10(13):eadk8264. PubMed ID: 38552011
[TBL] [Abstract][Full Text] [Related]
9. Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.
Kim J
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069255
[TBL] [Abstract][Full Text] [Related]
10. Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas.
Xu C; Gao Q; Wu Z; Lou W; Li X; Wang M; Wang N; Li Q
Transl Oncol; 2022 Dec; 26():101540. PubMed ID: 36115073
[TBL] [Abstract][Full Text] [Related]
11. Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.
Burska AN; Ilyassova B; Dildabek A; Khamijan M; Begimbetova D; Molnár F; Sarbassov DD
Cells; 2022 Nov; 11(21):. PubMed ID: 36359850
[TBL] [Abstract][Full Text] [Related]
12. Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility.
Ku AA; Hu HM; Zhao X; Shah KN; Kongara S; Wu D; McCormick F; Balmain A; Bandyopadhyay S
Nat Commun; 2020 May; 11(1):2375. PubMed ID: 32398776
[TBL] [Abstract][Full Text] [Related]
13. Iron out KRAS-driven cancer.
Lei G; Gan B
J Exp Med; 2022 Apr; 219(4):. PubMed ID: 35262627
[TBL] [Abstract][Full Text] [Related]
14. Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens.
Karimpour M; Totonchi M; Behmanesh M; Montazeri H
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37863651
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.
de Castro Carpeño J; Belda-Iniesta C
Transl Lung Cancer Res; 2013 Apr; 2(2):142-51. PubMed ID: 25806225
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer.
Gai X; Liu Y; Lan X; Chen L; Yuan T; Xu J; Li Y; Zheng Y; Yan Y; Yang L; Fu Y; Tang S; Cao S; Dai X; Zhu H; Geng M; Ding J; Pu C; Huang M
Cancer Res; 2024 Mar; ():. PubMed ID: 38502865
[TBL] [Abstract][Full Text] [Related]
17. CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells.
Liu X; Tian F; Cui J; Gong L; Xiang L; Fan B; Liu S; Zhan J; Zhou Y; Jiang B; Wang M; Sun G; Gong Y; Zou Y
Oncogene; 2023 Oct; 42(42):3113-3126. PubMed ID: 37653114
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking analysis of KRAS inhibitors for cancer management.
J Hakeem I; Alsharif FH; Aljadani M; Fahad Alabbas I; Faqihi MS; Aloufi AH; Almutairi WA; Akber AH; Alam Q
Bioinformation; 2023; 19(4):411-416. PubMed ID: 37822837
[TBL] [Abstract][Full Text] [Related]
19. Opening a new GATAway for treating KRAS-driven lung tumors.
Barbacid M
Cancer Cell; 2012 May; 21(5):598-600. PubMed ID: 22624710
[TBL] [Abstract][Full Text] [Related]
20. Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment.
Preet R; Dixon DA
Cell Mol Gastroenterol Hepatol; 2018; 5(4):647-648. PubMed ID: 29713668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
